Evidence Gap in Managing Lateral Pelvic Lymph Nodes in Rectal Cancer: a Systematic Review of Radiation Boost Strategies.
Sedat Alp Pinar, Tin-Ning Wong, Timothy Mitchell et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review assessed radiation dose escalation to radiologically suspicious lateral pelvic lymph nodes (LPLNs) during neoadjuvant chemoradiotherapy for locally advanced rectal cancer. It included 10 retrospective cohort studies with 482 patients receiving a boost. Boost doses ranged from 35.0 to 60.2 Gy; reported nodal response rates ranged from 62.3% to 100%. Comparative studies suggested improved local control and fewer LPLN recurrences, but the review found that evidence remains limited and heterogeneous, with no prospective evidence establishing the strategy’s safety, oncologic benefit, or role relative to lymph node dissection.
Key findings
- Ten retrospective cohort studies included 482 patients treated with radiation boosts to suspicious LPLNs.
- Boost doses ranged from 35.0 to 60.2 Gy, and nodal response rates ranged from 62.3% to 100%.
- Grade 2-3 toxicity rates ranged from 28.0% to 39.3%; one study reported a single Grade 4 adverse event.
- Comparative studies suggested better local control and reduced LPLN recurrence with radiation boost.
Why it matters
LPLN involvement predicts local recurrence, while surgical dissection can increase morbidity and is not widely adopted in Western practice. Radiation boost is a potential non-surgical approach, but the available findings do not establish its comparative benefit or safety. The review highlights the need for stronger evidence to guide selection between nodal dose escalation and dissection.
What to keep in mind
All included studies were retrospective, and substantial clinical heterogeneity limits interpretation. The review found no prospective evidence.